Proteomic profiling of human plasma extracellular vesicles identifies PF4 and C1R as novel biomarker in sarcopenia
Journal of Cachexia, Sarcopenia and Muscle · 2024
DOI: 10.1002/jcsm.13539 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2024. Verfasst von Paula Aparicio und 11 weiteren Autor:innen. Beteiligte Einrichtung: LAGENBIO Laboratory, Faculty of Veterinary, University of Zaragoza, Zaragoza, Spain. Hauptthemen laut MEDLINE: Sarcopenia, Extracellular Vesicles, Biomarkers, Proteomics. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Commission (Horizon 2020 framework Programme Marie Curie), Universidad de Zaragoza, Gobierno de España. Ministerio de Ciencia e Innovación.
Abstract (Originalsprache)
Background
Sarcopenia, the gradual and generalized loss of muscle mass and function with ageing, is one of the major health problems in older adults, given its high prevalence and substantial socioeconomic implications. Despite the extensive efforts to reach consensus on definition and diagnostic tests and cut‐offs for sarcopenia, there is an urgent and unmet need for non‐invasive, specific and sensitive biomarkers for the disease. Extracellular vesicles (EVs) are present in different biofluids including plasma, whose cargo reflects cellular physiology. This work analysed EV proteome in sarcopenia and robust patients in the search for differentially contained proteins that can be used to diagnose the disease.
Methods
Plasma small EVs (sEVs) from a total of 29 robust controls (aged 73.4 ± 5.6 years; 11 men and 18 women) and 49 sarcopenic patients (aged 82.3 ± 5.4 years; 15 men and 34 women) aged 65 years and older were isolated and their cargo was analysed by proteomics. Proteins whose concentration in sEVs was different between sarcopenic and robust patients were further validated using ELISA. The concentration of these candidates was correlated to the EWGSOP2 sarcopenia tests for low muscle strength and low physical performance, and receiver operating characteristic (ROC) curve analyses were carried out to evaluate their diagnostic power, sensitivity and specificity.
Results
Proteomic analysis identified 157 sEVs proteins in both sarcopenic and robust samples. Among them, 48 proteins had never been reported in the ExoCarta nor Vesiclepedia databases. Statistical analysis revealed eight proteins whose concentration was significantly different between groups: PF4 (log2 FC = 4.806), OIT3 (log2 FC = −1.161), MMRN1 (log2 FC = −1.982), MASP1 (log2 FC = −0.627), C1R (log2 FC = 1.830), SVEP1 (log2 FC = 1.295), VCAN (FC = 0.937) and SPTB (log2 FC = 1.243). Among them, platelet factor 4 (PF4) showed the lowest concentration while Complement C1r subcomponent (C1R) increased the most in sarcopenic patients, being these results confirmed by ELISA ( P = 1.07E‐09 and P = 0.001287, respectively). The concentrations of candidate proteins significantly correlated with EWGSOP2 tests currently used. ROC curve analysis showed an area under the curve of 0.8921 and 0.7476 for PF4 and C1R, respectively. Choosing the optimal for PF4, 80% sensitivity and 85.71% specificity was reached while the optimal cut‐off value of C1R would allow sarcopenia diagnosis with 75% sensitivity and 66.67% specificity.
Conclusions
Our results support the determination of EV PF4 and C1R as plasma diagnostic biomarkers in sarcopenia and open the door to investigate the role of the content of these vesicles in the pathogeny of the disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- LAGENBIO Laboratory, Faculty of Veterinary, University of Zaragoza, Zaragoza, Spain.
- Centre for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
- AgroFood Institute of Aragon (IA2), Zaragoza, Spain.
- Aragon Health Research Institute (IIS Aragon), Zaragoza, Spain.
- EXER-GENUD (Growth, Exercise, Nutrition and Development) Research Group, University of Zaragoza, Zaragoza, Spain.
- Faculty of Health Science, University of Zaragoza, Zaragoza, Spain.
ORCID-Profile: Paula Aparicio, Raquel Manzano
Förderung
- European Commission (Horizon 2020 framework Programme Marie Curie)
- Universidad de Zaragoza
- Gobierno de España. Ministerio de Ciencia e Innovación
- Gobierno de España. Ministerio de Economía, Industria y Competitividad
- Centro Universitario de la Defensa-Universidad de Zaragoza
- CIBERFES-Consorcio Centro de Investigación Biomédica en Red Fragilidad y Envejecimiento Saludable
- Instituto de Salud Carlos III and FEDER-Fondo Europeo de Desarrollo Regional 'Una manera de hacer Europa'
- CIBERNED-Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas
Zitieren
APA
Aparicio, P., Navarrete-Villanueva, D., Gómez-Cabello, A., López-Royo, T., Santamaría, E., Fernández-Irigoyen, J., Ausín, K., Arruebo, M., Sebastian, V., Vicente-Rodríguez, G., Osta, R., & Manzano, R. (2024). Proteomic profiling of human plasma extracellular vesicles identifies PF4 and C1R as novel biomarker in sarcopenia. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13539
Vancouver
Aparicio P, Navarrete-Villanueva D, Gómez-Cabello A, López-Royo T, Santamaría E, Fernández-Irigoyen J, et al. Proteomic profiling of human plasma extracellular vesicles identifies PF4 and C1R as novel biomarker in sarcopenia. Journal of Cachexia, Sarcopenia and Muscle. 2024. doi:10.1002/jcsm.13539
BibTeX
@article{Aparicio2024,
author = {Aparicio, Paula and Navarrete-Villanueva, David and Gómez-Cabello, Alba and López-Royo, Tresa and Santamaría, Enrique and Fernández-Irigoyen, Joaquín and Ausín, Karina and Arruebo, Manuel and Sebastian, Victor and Vicente-Rodríguez, Germán and Osta, Rosario and Manzano, Raquel},
title = {Proteomic profiling of human plasma extracellular vesicles identifies PF4 and C1R as novel biomarker in sarcopenia},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2024},
doi = {10.1002/jcsm.13539}
}
EUVIMED